A look at the best-selling drugs in 2017 shows the top spots dominated by monoclonal antibodies which, despite their age and looming competition, are still pulling in billions of dollars (FIG. 1a). The success of
these huge franchises is partly down to the ability of manufacturers to continue to raise prices in the United States, even on these long-established assets, while…

Para acessar a publicação na íntegra clique aqui

Fonte: 232 | APRIL 2018 | VOLUME 17 www.nature.com/nrd